How a Disrupted Gut Microbiome Quietly Destroys Your Kidneys Through Uric Acid

Uric acid is usually just a footnote in a blood panel, but for tens of millions of people worldwide, its accumulation sets off a chain of events that ends in damaged kidneys. A new review by J Quanli and YL Yin, published in Frontiers in Molecular Biosciences, argues that the gut microbiome sits at the center of that chain. The evidence is emerging rather than definitive, but the picture it draws is striking: the trillions of bacteria lining your intestines may be doing far more to control uric acid than any drug currently on the market.

Gut Microbiota Dysbiosis Raises Serum Uric Acid Through Multiple Pathways

About 25% of all uric acid in the body is excreted into the intestine rather than the kidneys, where bacteria including Lactobacillus and Bifidobacterium break it down and eliminate it. When that microbial community is disrupted, a condition called dysbiosis, this alternative excretion route collapses. But the damage goes further than simple arithmetic.

The review describes how gut microbes regulate uric acid metabolism through at least four interacting mechanisms: reducing uric acid production, enhancing the breakdown of purines before they can be converted to uric acid, influencing amino acid transport, and increasing direct uric acid excretion. In patients with gout and hyperuricemia, studies have consistently found increased abundance of Bacteroides and sharply reduced Faecalibacterium, a bacterium associated with anti-inflammatory short-chain fatty acid (SCFA) production. Bacteria like Clostridium and Ruminococcus that produce SCFAs are also depressed in hyperuricemia, tipping the microbial ecosystem toward a pro-inflammatory state that drives serum uric acid even higher.

One particularly pointed piece of experimental evidence: fecal microbiota transplants from hyperuricemic rats into healthy recipients significantly elevated uric acid levels in those previously normal animals. The microbiome alone was enough to reproduce the metabolic dysfunction.

Kidney Damage Tied to a Leaky Gut and Chronic Inflammation

The kidneys bear the brunt of sustained hyperuricemia, and according to the review, the gut-to-kidney pathway runs through a compromised intestinal barrier. Intestinal microbial dysbiosis in chronic kidney disease has been identified in mouse models as a key factor linking high-purine diets to progressive renal injury. In the current review's framework, dysbiosis physically loosens the tight junctions between intestinal cells, allowing bacterial products, most notably lipopolysaccharide (LPS), to leak into the bloodstream.

Circulating LPS triggers systemic chronic inflammation, which then disrupts the expression of uric acid transporter proteins in the kidney, including URAT1, GLUT9, OAT1, OCT1, and ABCG2. When these transporters malfunction, the kidney retains more uric acid than it should, compounding the problem. The review frames this as a self-reinforcing loop: elevated uric acid worsens gut dysbiosis by inducing intestinal inflammation and altering gut pH, which in turn promotes pro-inflammatory bacterial overgrowth and further impairs transporter function.

The human cost of this cascade is significant. Population data on the global burden of gout show that disability-adjusted life years attributable to gout linked to kidney dysfunction increased 2.5-fold between 1990 and 2021, affecting both younger and older populations, with approximately 55.8 million people diagnosed with gout globally as of 2020.

How Xanthine Dehydrogenase and Specific Bacteria Interact to Overproduce Uric Acid

The enzyme xanthine dehydrogenase is the final enzymatic step in converting purines to uric acid, and it is highly expressed in patients with gout. The review raises the hypothesis that increased abundance of Alistipes, a genus consistently found elevated in hyperuricemia, may upregulate xanthine dehydrogenase activity, adding a microbial amplifier to an already overactive biochemical pathway.

Landmark preclinical studies on gut microbiota in urate elimination have identified purine-degrading bacteria, predominantly from the Bacillota phylum, as having significant urate-lowering potential. When these bacteria are depleted, as they characteristically are in dysbiosis, the body loses a natural brake on uric acid production precisely at the moment it needs one most. The review notes this interaction between microbial composition and enzymatic activity as one of the more mechanistically interesting threads in the field, though the exact causal sequences remain to be worked out.

Fecal Transplants and Probiotics as Emerging Therapeutic Targets

Given the causal role that dysbiosis appears to play, restoring a healthy gut microbiome is an obvious therapeutic target, and several approaches are under investigation. Fecal microbiota transplantation (FMT) has shown the most striking results in experimental settings: FMT decreased serum uric acid, relieved gout symptoms, and restored intestinal barrier function in preclinical models. The transplantation of healthy microbiota essentially reverses the chain of events described above.

Probiotics are also drawing attention. Compound probiotic supplementation in mouse models of renal failure attenuated hyperuricemia-associated renal dysfunction and interstitial fibrosis by restoring gut microbiota homeostasis and preserving metabolic pathways. Specific strains, including Lactobacillus plantarum, have shown uric acid-lowering effects in controlled experiments. Prebiotics, which selectively feed beneficial bacteria, are also being tested as a way to inhibit purine metabolism and reduce inflammatory markers.

The review is careful to note that conventional gout medications, such as allopurinol and febuxostat, themselves alter gut microbiota composition, raising the possibility that some of their therapeutic benefit, or their side effects, may be microbiome-mediated rather than purely pharmacological.

Open Questions About Mechanism, Variability, and Scalability

The picture assembled by Quanli and Yin is coherent, but they are candid about how much remains unresolved. The exact mechanisms by which different microbial species influence hyperuricemia pathogenesis have not been established with precision; most of the causal evidence comes from animal models and observational human studies rather than large-scale interventional trials. Gut microbiota transplantation faces practical bottlenecks around immunogenicity, individual variability in microbial engraftment, and formulation technology that make clinical rollout uncertain.

The gut-renal axis in hyperuricemia is a compelling framework, and the therapeutic potential is real. But the field is still at the stage of mapping the territory rather than charting a confirmed route through it. Whether restoring specific bacterial taxa, or transplanting entire microbial communities, translates into clinically meaningful reductions in kidney disease progression remains an open and pressing question.

Evidence rating

EMERGING — 80/100

Caveats:

• This is a narrative review, not a clinical trial — it synthesizes existing studies rather than generating new experimental data.
• Many proposed mechanisms, including the link between specific bacterial taxa and uric acid transporter regulation, remain observational or animal-derived and have not been confirmed in controlled human trials.
• Funding source was not disclosed by the authors.
• Fecal microbiota transplantation findings cited here are largely from animal models; human translation remains limited.

Narrative review synthesizing clinical and preclinical studies on gut microbiota dysbiosis in hyperuricemic nephropathy. The mechanistic pathways proposed — including transporter regulation and LPS-mediated inflammation — are supported by observational and animal data but not yet confirmed in powered, controlled human trials. Replication of specific findings across independent cohorts remains limited.

References

1. J Quanli, YL Yin (2026). The Role of Gut Microbiota Dysbiosis in the Pathogenesis of Hyperuricemic Nephropathy. Frontiers in Molecular Biosciences. https://doi.org/10.3389/fmolb.2026.1872377
2. Caihong Hu (2024). Regulating uric acid. eLife. https://doi.org/10.7554/elife.104493
3. Ping Liu, Jianli Yang, Meiping Jin, et al. (2024). Alterations in the gut microbiome and metabolism profiles reveal the possible molecular mechanism of renal injury induced by hyperuricemia in a mouse model of renal insufficiency. Renal Failure. https://doi.org/10.1080/0886022x.2024.2387429
4. Jiaxian Xu, Mingming Lei, Dandan Xu (2025). Trends in the global burden of gout attributable to kidney dysfunction, 1990-2021: a population-based analysis. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2025.1677340
5. Robert Terkeltaub, Dylan Dodd (2025). The Gut Microbiome in Hyperuricemia and Gout. Arthritis & Rheumatology. https://doi.org/10.1002/art.43118
6. Ping Liu, Ping Hu, Meiping Jin, et al. (2025). Compound probiotics alleviate hyperuricemia-induced renal injury via restoring gut microbiota and metabolism. BMC Microbiology. https://doi.org/10.1186/s12866-025-04012-5